Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnetic targeting of autologous bone marrow-derived mesenchymal stem cells in knee osteoarthritis
jRCT2063210037Completed
- Sponsor
- Japan Tissue Engineering Co., Ltd.
- Start
- Oct 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in knee osteoarthritis (OA), sponsored by Japan Tissue Engineering Co., Ltd. Primary endpoints: Incidence rate of adverse events and defects and Significant adverse events specific to regenerative medical products. Started Oct 2021; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2063210037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063210037.